CTLA4 and melanoma: In this study, we have utilized high-dimensional mass cytometry to interrogate circulating immune cells and the systemic immune responses in patients with melanoma who did and did not develop colitis on-treatment with combination therapy of anti–CTLA-4 and anti–PD-1 (18).